Shopping Cart
- Remove All
- Your shopping cart is currently empty
Edaglitazone (R-483) is an orally active, selective and potent PPARγ agonist showing affinity for both PPARα and PPARγ. Edaglitazone displays antiplatelet activity and can be used in studies of diabetes mellitus and obesity.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $358 | 35 days |
Description | Edaglitazone (R-483) is an orally active, selective and potent PPARγ agonist showing affinity for both PPARα and PPARγ. Edaglitazone displays antiplatelet activity and can be used in studies of diabetes mellitus and obesity. |
Targets&IC50 | PPARα:1053 nM (EC50), PPARγ:35.6 nM (EC50) |
In vitro | METHODS: To elucidate the mechanism of the antiplatelet effect of edaglitazone, platelet cAMP levels were assessed using edaglitazone (3, 6, and 12 μM), Consistent with the aggregation assay, RESULTS: Edaglitazone increased platelet cAMP levels in a concentration-dependent manner, suggesting that its antiplatelet effect is partly mediated by the regulation of cAMP levels. [1] |
Alias | R-483, Edaglitazone sodium, BM-13.1258 |
Molecular Weight | 464.56 |
Formula | C24H20N2O4S2 |
Cas No. | 213411-83-7 |
Smiles | O=C1SC(C(=O)N1)CC2=CC=C(OCCC=3N=C(OC3C)C=4C=CC=CC4)C=5C=CSC52 |
Relative Density. | 1.374 g/cm3 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.